Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
Authors:
Michal Vrablík; Vladimír Bláha; Renata Cífková; Tomáš Freiberger; David Karásek; Pavel Kraml; Jan Piťha; Hana Rosolová; Vladimír Soška; Tomáš Štulc; Lukáš Zlatohlávek Za Výbor Čsat; Jana Mašková
Published in:
AtheroRev 2023; 8(2): 66-76
Category:
Guidelines
Sources
Číselné označení citované literatury odkazuje na citace v originální verzi Konsenzu:
Kronenberg F, Mora S, Stroes ESG et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J 2022 : 43(39): 3925–3946. Dostupné z DOI: https://doi.org/10.1093/eurheartj/ehac361.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2023 Issue 2
Most read in this issue
- Bempedoic acid in the context of current hypolipidemic treatment options and the results of the CLEAR OUTCOMES trial
- Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
- The importance of nonstatin therapies for LDL-cholesterol lowering in the management of very high and high atherosclerotic cardiovascular risk
- Hyperlipidemic crisis as a risk factor for acute pancreatitis